Moderna (MRNA)
Moderna (NASDAQ: MRNA)
Founded: September 2010
Headquarters: Cambridge, Massachusetts, USA
Focus Area: Development of mRNA-based therapeutics
🔬 Key Pipelines / Technologies
| Pipeline | Indication | Clinical Stage | Notes |
|---|---|---|---|
| mRNA-1273 | COVID-19 | Approved | Spikevax |
| mRNA-1345 | RSV | Phase 3 | Final results expected in H2 2025 |
| mRNA-4157 | Cancer therapy | Phase 2 | Personalized cancer vaccine |
- Source: Moderna Pipeline
📅 Recent Major Events
| Date | Event |
|---|---|
| 2025.02.15 | Announced positive interim Phase 3 results for mRNA-1345 – strong efficacy |
| 2025.01.20 | Reported positive Phase 2 results for mRNA-4157 in combination with checkpoint inhibitor |
💰 Financial Information
| Item | Value |
|---|---|
| Market Cap | ~$130 billion |
| Cash Holdings | ~$18 billion |
| Annual R&D Spending | ~$4 billion |
| Operating Loss (2024) | ~$3 billion |
| Number of Employees | ~3,200 |
| Estimated Cash Runway | ~5 years |
Formula = (Current Assets – Current Liabilities) / Operating Loss (Previous Year)
Source: Yahoo Finance
Source: Moderna 2024 Annual Report
🚀 Upcoming Catalysts / Risk Factors
- Upcoming Milestones:
- H2 2025: Final Phase 3 results expected for mRNA-1345
- Late 2025: Planned Phase 3 entry for mRNA-4157
- Risk Factors:
- Declining demand for COVID-19 vaccines may impact revenue
- Potential delays or failures in pipeline clinical trials
Source: Moderna 2024 Annual Report
This content is provided for informational purposes only and does not constitute investment advice.
All investment decisions are solely the responsibility of the reader, and any resulting gains or losses belong to the investor.
Updated: 2025-03-22